Overview

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (EB).
Phase:
Phase 2
Details
Lead Sponsor:
InMed Pharmaceuticals Inc.